Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

publishing date : 2021 - 10 - 21    symbols : SNYNF    save search

John King is recognized by Continental Who's Who
Published: 2021-10-21 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 480 twitter stocktwits trandingview |
Health Technology
| | O: -1.1% H: 0.0% C: -0.41%
SNY | News | $47.27 -0.88% 130K twitter stocktwits trandingview |
Health Technology
| | O: 0.41% H: 0.0% C: 0.0%


Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
Published: 2021-10-21 (Crawled : 14:00) - biospace.com/
SNY | News | $47.27 -0.88% 130K twitter stocktwits trandingview |
Health Technology
| | O: -0.08% H: 0.41% C: 0.41%
LGND | $69.72 -0.24% 3.7K twitter stocktwits trandingview |
Health Technology
| | O: -0.17% H: 1.8% C: 0.91%

covid collaboration technology
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
SNY | News | $47.27 -0.88% 130K twitter stocktwits trandingview |
Health Technology
| | O: -0.08% H: 0.41% C: 0.41%


ReCode Scores $80 Million to Advance mRNA-Based Cystic Fibrosis, PCD Programs
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
SNY | News | $47.27 -0.88% 130K twitter stocktwits trandingview |
Health Technology
| | O: -0.08% H: 0.41% C: 0.41%

fibrosis cystic fibrosis
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Published: 2021-10-21 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.085 -0.89% 2.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.6% H: 0.08% C: -0.45%
SNY | News | $47.27 -0.88% 130K twitter stocktwits trandingview |
Health Technology
| | O: -0.08% H: 0.41% C: 0.41%
BNTX | News | $89.23 0.84% 45K twitter stocktwits trandingview |
Health Technology
| | O: 2.66% H: 3.69% C: 3.53%

covid vaccine phase 3 trial
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates
Published: 2021-10-21 (Crawled : 09:00) - biospace.com/
SNY | News | $47.27 -0.88% 130K twitter stocktwits trandingview |
Health Technology
| | O: -0.08% H: 0.41% C: 0.41%

fibrosis collaboration drug
Gainers vs Losers
66% 34%

Top 10 Gainers
CZOO | $11.44 129.26% 4.6M twitter stocktwits trandingview |

AMST | $3.4 70.0% 51M twitter stocktwits trandingview |
Technology Services

BOF | $1.78 52.14% 15M twitter stocktwits trandingview |

SYRA | $1.5 51.23% 1M twitter stocktwits trandingview |
n/a

CSSE 4 | $0.23 51.02% 46M twitter stocktwits trandingview |
Consumer Services

RILY | $30.325 39.62% 6.8M twitter stocktwits trandingview |
Finance

LICN | $0.76 35.71% 6.2M twitter stocktwits trandingview |

TROO | $1.41 29.36% 280K twitter stocktwits trandingview |
Manufacturing

MULN | News | $3.53 29.3% 4.8M twitter stocktwits trandingview |
Information

RBBN 4 | $3.21 24.9% 580K twitter stocktwits trandingview |
Electronic Technology


Your saved searches
Save your searches and get alerts when important news are released.